Obtains Additional Indication For Rexulti In Japan As An Adjunctive Treatment For Agitation Associated With Dementia Due To Alzheimer's Disease
24/09/2024 07:02
Sept 24 (Reuters) - Otsuka Holdings Co Ltd 4578.T :
* OTSUKA HOLDINGS CO LTD- OBTAINS ADDITIONAL INDICATION FOR
REXULTI IN JAPAN AS AN ADJUNCTIVE TREATMENT FOR AGITATION
ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE
Source text for Eikon: ID:nTSux8f8ab
Further company coverage: 4578.T
(Reporting by Rocky Swift)
((rocky.swift@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug